Starpharma (SPHRY) Stock Price, News & Analysis

Company Overview

Starpharma (OTCMKTS:SPHRY) is an Australian biotechnology company specializing in the development and commercialization of dendrimer-based products for pharmaceutical, consumer health, and life sciences applications. The company’s proprietary dendrimer nanotechnology platform enables precise molecular engineering to improve drug delivery, enhance antiviral activity and create novel therapeutics. Starpharma’s R&D efforts span antiviral compounds, oncology formulations and antimicrobial coatings designed to address critical unmet medical needs.

One of Starpharma’s flagship products is VivaGel®, a topical antiviral and antibacterial agent formulated to prevent transmission of pathogens responsible for herpes simplex virus and bacterial vaginosis. VivaGel® has been commercialized in multiple regions under license agreements with leading consumer health companies. In the pharmaceutical sector, Starpharma’s DEP® (Drug-Enhanced Performance) technology has been applied to oncology agents such as docetaxel, in collaboration with global partners including AstraZeneca and Merck, to improve therapeutic index, reduce toxicity and enhance treatment outcomes.

Headquartered in Melbourne, Australia, Starpharma operates a regulatory and business development office in the United States, supporting clinical trials and product registrations across North America, Europe and Asia. The company’s global footprint includes strategic partnerships for manufacturing, distribution and research collaborations that leverage its dendrimer expertise to accelerate product development and market access.

Founded in 1997, Starpharma has evolved from an academic laboratory spin-out into a publicly traded innovator in nanomedicine. The company is led by Managing Director and Chief Executive Officer Dr. Jackie Fairley, supported by a board of directors with extensive experience in pharmaceutical development, regulatory affairs and corporate governance. Starpharma continues to expand its pipeline through in-house research and strategic collaborations aimed at delivering next-generation therapeutics and preventive solutions.

Key Stats

• Today's Range: $0.67 to $0.67
• 50-Day Range: $0.47 to $0.64
• 52-Week Range: $0.47 to $0.80
• Volume: 100 shs
• Average Volume: 1,381 shs
• Market Capitalization: $28.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SPHRY Stock Analysis - Frequently Asked Questions

How have SPHRY shares performed this year?

Starpharma's stock was trading at $0.6433 on January 1st, 2025. Since then, SPHRY stock has increased by 4.5% and is now trading at $0.6720.

How do I buy shares of Starpharma?

Shares of SPHRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/15/2025
• Next Earnings (Estimated): 8/20/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SPHRY
• CIK: N/A
• Web: www.starpharma.com
• Phone: (138) 532-2700
• Fax: 61-3-9510-5955
• Employees: 45
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.07
• Current Ratio: 5.41
• Quick Ratio: 4.93

Sales & Book Value

• Annual Sales: $6.40 million
• Price / Sales: 4.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.45 per share
• Price / Book: 1.49

Miscellaneous

• Outstanding Shares: 41,820,000
• Free Float: N/A
• Market Cap: $28.10 million
• Optionable: Not Optionable
• Beta: 0.76